Camp4 Therapeutics Corporation (CAMP)

NASDAQ: CAMP · Real-Time Price · USD
3.380
-0.240 (-6.63%)
At close: Oct 14, 2025, 4:00 PM EDT
3.485
+0.105 (3.12%)
Pre-market: Oct 15, 2025, 8:17 AM EDT
-6.63%
Market Cap158.33M
Revenue (ttm)3.01M
Net Income (ttm)-51.78M
Shares Out 46.84M
EPS (ttm)-3.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume160,223
Open3.520
Previous Close3.620
Day's Range3.310 - 3.604
52-Week Range1.305 - 12.300
Betan/a
AnalystsBuy
Price Target13.40 (+296.45%)
Earnings DateNov 20, 2025

About CAMP

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was inco... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 11, 2024
Employees 55
Stock Exchange NASDAQ
Ticker Symbol CAMP
Full Company Profile

Financial Performance

In 2024, Camp4 Therapeutics's revenue was $652,000, an increase of 86.29% compared to the previous year's $350,000. Losses were -$51.79 million, 5.07% more than in 2023.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for CAMP stock is "Buy." The 12-month stock price target is $13.4, which is an increase of 296.45% from the latest price.

Price Target
$13.4
(296.45% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation  (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regul...

14 days ago - GlobeNewsWire

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $5...

5 weeks ago - GlobeNewsWire

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targetin...

2 months ago - GlobeNewsWire

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes

5 months ago - GlobeNewsWire

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting...

5 months ago - GlobeNewsWire

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression

6 months ago - GlobeNewsWire

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: EWTXGNFT
6 months ago - Benzinga

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic...

7 months ago - GlobeNewsWire

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D.

7 months ago - GlobeNewsWire

CORRECTION - CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108

7 months ago - GlobeNewsWire

CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025

Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108

7 months ago - GlobeNewsWire

CAMP4 to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense ...

8 months ago - GlobeNewsWire

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotid...

10 months ago - GlobeNewsWire

CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeuti...

11 months ago - GlobeNewsWire

CAMP4 Reports Third Quarter 2024 Financial Results

- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q...

11 months ago - GlobeNewsWire

CAMP4 Analyst Highlights Rare Disease Platform Potential

In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.

1 year ago - Benzinga

CAMP4 Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting th...

1 year ago - GlobeNewsWire

Camp4 Therapeutics Targets IPO On Early Positive Results

Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive...

1 year ago - Seeking Alpha